 NEWARK, Calif., June 11, 2021 PRNewswire -- Protagonist Therapeutics Nasdaq:PTGX Protagonist or the Company today announced updated results from the ongoing Phase 2 study of rusfertide, an investigational new drug being evaluated for the treatment of polycythemia vera PV. 